MedTrace Logo

Safety and Efficacy of Baricitinib After Endovascular Treatment in Acute Anterior Circulation Large Vessel Occlusion: A Multicenter, Randomized Controlled Clinical Trial

NCT07449910 · Status: NOT_YET_RECRUITING · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 750

Last updated 2026-03-04

No results posted yet for this study

Summary

The primary purpose of this study is to evaluate the efficacy and safety of Baricitinib combined with endovascular therapy in patients with acute anterior circulation large vessel occlusion, to address futile recanalization with priority, and to elucidating the mechanism of JAK/STAT pathway inhibition on neuroprotection and inflammatory regulation.

Conditions

  • Acute Ichemic Stroke
  • Anterior Cerebral Artery Stroke
  • Baricitinib

Interventions

DRUG

2mg Baricitinib

One 2mg Baricitinib tablet and one 2mg placebo tablet are given three times a day, last for 5±2 days.

DRUG

4mg Baricitinib

Two 2mg Baricitinib tablets are given three times a day, last for 5±2 days.

DRUG

Placebo

Two 2mg placebo tablets are given three times a day, last for 5±2 days.

OTHER

Guideline-based therapy

Guideline-based therapy including EVT treatment is determined by the physician.

Sponsors & Collaborators

  • The First Affiliated Hospital of University of Science and Technology of China

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-03-17
Primary Completion
2027-08-17
Completion
2028-01-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07449910 on ClinicalTrials.gov